Published in J Neurol on December 01, 2008
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
Multiple sclerosis. J Clin Invest (2004) 2.48
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30
B cells and multiple sclerosis. Lancet Neurol (2008) 2.28
Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain (2005) 1.79
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler (2006) 1.70
Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol (2008) 1.43
Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy. J Clin Immunol (2000) 1.42
Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant (2005) 1.37
Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood (2002) 1.12
Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl (1997) 1.11
Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol (2002) 1.10
Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. Mult Scler (2007) 0.95
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler (2005) 0.92
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult Scler (2007) 0.92
Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol (1992) 0.91
Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges. Curr Opin Neurol (2003) 0.86
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol (2007) 4.87
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol (2003) 4.17
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2008) 2.20
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol (2009) 2.06
Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci (2002) 1.99
Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J (2005) 1.98
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
Development of biomarkers in multiple sclerosis. Brain (2004) 1.78
Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One (2008) 1.72
Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain (2003) 1.71
The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One (2012) 1.67
[Criteria for evidence-based patient information]. Z Arztl Fortbild Qualitatssich (2005) 1.64
Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet (2003) 1.59
Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol (2004) 1.56
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54
Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry (2011) 1.53
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain (2006) 1.53
Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: implications for the initiation of the autoimmune response in multiple sclerosis. Eur J Immunol (2008) 1.51
Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2005) 1.45
Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood (2007) 1.44
Clinical nurse specialists and the practice of community nurses. J Adv Nurs (2006) 1.42
Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation. Leuk Lymphoma (2010) 1.41
Participation preferences of patients with acute and chronic conditions. Health Expect (2007) 1.40
Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls. J Neuroimmunol (2003) 1.39
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica (2009) 1.34
A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol (2012) 1.34
EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med (2008) 1.33
Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism? Stem Cells Dev (2005) 1.30
JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol (2013) 1.29
Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J Neurol Sci (2004) 1.28
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation (2006) 1.24
Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain (2011) 1.22
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain (2010) 1.21
T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol (2012) 1.21
Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures. Mult Scler (2003) 1.19
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood (2005) 1.18
Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J (2011) 1.17
Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol (2011) 1.17
Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol (2009) 1.16
A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes. Mol Immunol (2004) 1.15
Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol (2007) 1.11
The value of animal models for drug development in multiple sclerosis. Brain (2006) 1.11
Patients' and observers' perceptions of involvement differ. Validation study on inter-relating measures for shared decision making. PLoS One (2011) 1.11
Evidence-based patient information about treatment of multiple sclerosis--a phase one study on comprehension and emotional responses. Patient Educ Couns (2005) 1.10
Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr Rheumatol Online J (2007) 1.09
Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol (2004) 1.07
Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol (2005) 1.07
Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol (2011) 1.07
The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol (2005) 1.05
Application of support vector machines for T-cell epitopes prediction. Bioinformatics (2003) 1.05
Infectious causes of multiple sclerosis. Lancet Neurol (2006) 1.04
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clin Neuropharmacol (2012) 1.01
Modafinil effects in multiple sclerosis patients with fatigue. J Neurol (2009) 1.01
Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol (2007) 1.00
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. Exp Hematol (2012) 0.98
Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes. J Infect Dis (2006) 0.98
MAPPIN'SDM--the multifocal approach to sharing in shared decision making. PLoS One (2012) 0.97
Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae. Am J Pathol (2007) 0.95
High production of CXCL13 in blood and brain during persistent infection with the relapsing fever spirochete Borrelia turicatae. J Neuropathol Exp Neurol (2007) 0.95
Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol (2008) 0.95
Spotlight on anti-CD25: daclizumab in MS. Int MS J (2008) 0.94
Training-dependent plasticity in patients with multiple sclerosis. Brain (2004) 0.94
Information provision for people with multiple sclerosis. Cochrane Database Syst Rev (2014) 0.93
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol (2006) 0.93
Cerebrospinal fluid-infiltrating CD4+ T cells recognize Borrelia burgdorferi lysine-enriched protein domains and central nervous system autoantigens in early lyme encephalitis. Infect Immun (2006) 0.92
HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J Neuroimmunol (2005) 0.92
Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity. PLoS Pathog (2005) 0.92
Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments. PLoS One (2013) 0.92
Depressive syndromes in neurological disorders. Eur Arch Psychiatry Clin Neurosci (2013) 0.91
TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol (2007) 0.91
Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis. J Immunol (2010) 0.91
Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry (2013) 0.90
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol (2009) 0.90
Genomics in multiple sclerosis--current state and future directions. J Neuroimmunol (2007) 0.90
Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. J Proteome Res (2013) 0.89
Borrelia burgdorferi Induces TLR1 and TLR2 in human microglia and peripheral blood monocytes but differentially regulates HLA-class II expression. J Neuropathol Exp Neurol (2006) 0.89
Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr Treat Options Neurol (2013) 0.89
Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol (2007) 0.89
Implementation of a patient education program on multiple sclerosis relapse management. Patient Educ Couns (2011) 0.89
Responsiveness of patient-based and external rating scales in multiple sclerosis: head-to-head comparison in three clinical settings. J Neurol Sci (2009) 0.89
Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol (2003) 0.89
Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies. Anticancer Res (2009) 0.88
Kinematic specificity of cortical reorganization associated with motor training. Neuroimage (2004) 0.88
Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors. Leuk Lymphoma (2009) 0.88
Antigen-specific therapies in MS - Current concepts and novel approaches. J Neurol Sci (2008) 0.88
Use of combinatorial peptide libraries for T-cell epitope mapping. Methods (2003) 0.87